SEC Form 4 · accession 0001615774-18-000382
Ensysce Biosciences, Inc. · ENSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Daniel B. Silvers
Officer — Chief Executive Officer · Director
MLCP GLL Funding LLC
Other
Period of report
Jan 15, 2018
Accepted (ET)
Jan 17, 2018 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001716947
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 15, 2018 | J | 171,832 | $0.00 | D | 1,128,370 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As contemplated by the securities subscription agreement between each reporting person and the Company, 171,832 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the "Sponsor"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.
- F2Represents 887,127 shares of common stock held by the Sponsor Affiliate. Represents 241,243 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by Daniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest.